Format

Send to

Choose Destination
J Med Virol. 2012 Feb;84(2):194-7. doi: 10.1002/jmv.23188.

Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.

Author information

1
Department of Clinical Immunology, Hôpital Henri Mondor, Créteil, France. anne-sophie.lascaux@hmn.aphp.fr

Abstract

Aciclovir (ACV)-resistant Herpes simplex virus type-2 (HSV-2) infections are observed commonly in patients also infected with HIV-1. The use of foscarnet (FOS) in these patients may also lead to resistance. This situation can become a difficult therapeutic challenge. Four cases of patients infected with HIV and with mucocutaneous HSV-2 resistant to ACV and FOS are reported. These patients were treated successfully with topical 5% imiquimod. Imiquimod treatment also appeared to delay the time to recurrence of HSV lesions.

PMID:
22170537
DOI:
10.1002/jmv.23188
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center